Insider Transactions in Q1 2024 at Iovance Biotherapeutics, Inc. (IOVA)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 04
2024
|
Frederick G Vogt Interim CEO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
11,449
-8.13%
|
$183,184
$16.96 P/Share
|
|
Mar 04
2024
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
41,662
+22.83%
|
-
|
|
Mar 04
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,053
-16.36%
|
$128,848
$16.96 P/Share
|
|
Mar 04
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,623
+24.09%
|
-
|
|
Mar 04
2024
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,287
-16.59%
|
$116,592
$16.96 P/Share
|
|
Mar 04
2024
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,061
+24.25%
|
-
|
|
Feb 20
2024
|
Merrill A Mcpeak Director |
BUY
Open market or private purchase
|
Direct |
250,000
+43.85%
|
$2,250,000
$9.15 P/Share
|
|
Feb 20
2024
|
Iain D. Dukes Director |
BUY
Open market or private purchase
|
Direct |
32,000
+37.21%
|
$288,000
$9.15 P/Share
|
|
Feb 20
2024
|
Wayne P. Rothbaum Director |
BUY
Open market or private purchase
|
Indirect |
5,000,000
+15.12%
|
$45,000,000
$9.15 P/Share
|
|
Jan 16
2024
|
Frederick G Vogt Interim CEO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
6,530
-6.18%
|
$52,240
$8.37 P/Share
|
|
Jan 16
2024
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,834
+16.47%
|
-
|
|
Jan 16
2024
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,577
-5.02%
|
$12,616
$8.37 P/Share
|
|
Jan 16
2024
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,813
+8.21%
|
-
|
|
Jan 16
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,577
-4.48%
|
$12,616
$8.37 P/Share
|
|
Jan 16
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,813
+7.4%
|
-
|